Quanterix Corp
QTRX6.040USD
+0.180+3.07%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
234.36MValor de mercado
PerdaP/L TTM
Mais detalhes de Quanterix Corp Empresa
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Informações da empresa
Código da empresaQTRX
Nome da EmpresaQuanterix Corp
Data de listagemDec 07, 2017
CEODr. Masoud Toloue, Ph.D.
Número de funcionários471
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço900 Middlesex Turnpike
CidadeBILLERICA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal01821
Telefone16173019400
Sitehttps://www.quanterix.com/
Código da empresaQTRX
Data de listagemDec 07, 2017
CEODr. Masoud Toloue, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David R. Walt, Ph.D.
Dr. David R. Walt, Ph.D.
Independent Director
Independent Director
1.86M
+0.12%
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.40K
-0.44%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Independent Chairman of the Board
Independent Chairman of the Board
130.34K
+3.33%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
28.65K
--
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
27.40K
--
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
26.41K
+20.04%
Mr. Jeffrey Thomas (Jeff) Elliott
Mr. Jeffrey Thomas (Jeff) Elliott
Independent Director
Independent Director
19.42K
+62.04%
Ms. Vandana Sriram, CPA
Ms. Vandana Sriram, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
9.28K
-2.41%
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David R. Walt, Ph.D.
Dr. David R. Walt, Ph.D.
Independent Director
Independent Director
1.86M
+0.12%
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.40K
-0.44%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Independent Chairman of the Board
Independent Chairman of the Board
130.34K
+3.33%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
28.65K
--
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
27.40K
--
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
26.41K
+20.04%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
20.74M
68.51%
Service and other revenue
8.76M
28.95%
Collaboration and license revenue
771.00K
2.55%
Por RegiãoUSD
Nome
Receita
Proporção
North America
19.38M
64.01%
EMEA
6.63M
21.92%
Asia Pacific
4.26M
14.07%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
20.74M
68.51%
Service and other revenue
8.76M
28.95%
Collaboration and license revenue
771.00K
2.55%
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Columbia Threadneedle Investments (UK)
6.49%
Portolan Capital Management, L.L.C.
6.41%
BlackRock Institutional Trust Company, N.A.
5.81%
The Vanguard Group, Inc.
5.47%
Kent Lake PR LLC
4.52%
Other
71.29%
Investidores
Investidores
Proporção
Columbia Threadneedle Investments (UK)
6.49%
Portolan Capital Management, L.L.C.
6.41%
BlackRock Institutional Trust Company, N.A.
5.81%
The Vanguard Group, Inc.
5.47%
Kent Lake PR LLC
4.52%
Other
71.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
30.87%
Investment Advisor
25.39%
Hedge Fund
12.76%
Individual Investor
6.60%
Research Firm
3.49%
Pension Fund
0.35%
Bank and Trust
0.21%
Family Office
0.13%
Venture Capital
0.05%
Other
20.15%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
391
37.62M
83.70%
-11.91M
2025Q1
401
40.45M
104.19%
-6.42M
2024Q4
388
38.02M
98.63%
-6.28M
2024Q3
386
36.47M
95.03%
-5.94M
2024Q2
394
35.66M
93.20%
-9.57M
2024Q1
395
35.56M
93.43%
-9.17M
2023Q4
388
34.77M
91.99%
-10.35M
2023Q3
382
36.53M
97.35%
-9.84M
2023Q2
388
36.74M
98.24%
-9.95M
2023Q1
389
37.25M
100.03%
-8.36M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Columbia Threadneedle Investments (UK)
3.00M
7.72%
+237.57K
+8.60%
Mar 31, 2025
Portolan Capital Management, L.L.C.
2.96M
7.63%
+375.57K
+14.51%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.68M
6.91%
-89.03K
-3.21%
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
6.5%
+316.41K
+14.32%
Mar 31, 2025
Kent Lake PR LLC
2.92M
7.53%
+279.82K
+10.58%
Mar 31, 2025
Walt (David R)
1.86M
4.79%
+370.00K
+24.84%
Jun 13, 2025
William Blair Investment Management, LLC
1.11M
2.85%
+43.96K
+4.14%
Mar 31, 2025
UBS Financial Services, Inc.
1.11M
2.87%
+186.90K
+20.14%
Mar 31, 2025
Easterly Investment Partners LLC
1.33M
3.41%
+370.63K
+38.81%
Mar 31, 2025
Invenomic Capital Management LP
902.04K
2.32%
+546.67K
+153.83%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.58%
iShares Micro-Cap ETF
0.06%
Fidelity Enhanced Small Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.58%
iShares Micro-Cap ETF
Proporção0.06%
Fidelity Enhanced Small Cap ETF
Proporção0.04%
Avantis US Small Cap Equity ETF
Proporção0.03%
iShares Biotechnology ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
Schwab U.S. Small-Cap ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
